Summit Therapeutics stock
Price history
−36.64% over the period1 year: from $16.95 (November 17, 2025) to $10.74 (November 17, 2026), −36.64%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $10.74 |
| October 30, 2026 | $16.03 |
| September 30, 2026 | $16.91 |
| August 31, 2026 | $13.62 |
| July 31, 2026 | $13.02 |
| June 30, 2026 | $14.57 |
| May 29, 2026 | $17.54 |
| April 30, 2026 | $21.46 |
| March 31, 2026 | $18.96 |
| February 27, 2026 | $16.59 |
| January 30, 2026 | $14.48 |
| December 31, 2025 | $17.49 |
| November 28, 2025 | $17.89 |
| November 17, 2025 | $16.95 |
At a glance
The company
Biopharmaceutical company developing ivonescimab, a bispecific antibody combining immunotherapy and anti-angiogenesis for treating lung and colorectal cancers
Latest results
Quarter to September 30, 2026 · EPS -$0.19 (estimate -$0.29)
TickerLandia's take on Summit Therapeutics
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−63.50% from the 52-week high
Analysts · 17 analysts
Average target$29.54+176.88% vs. price
Buy 11 · Hold 6 · Sell 0 · Buy
TickerLandia Fingerprint: Summit Therapeutics
Compared with similar companies: very high risk, very weak momentum, and very low profitability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Profitabilityvery low14
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 0.0% 5 ROE −220.0% 4 ROA −112.0% 1 Operating margin 0.0% 31 Net margin 0.0% 31 Financial strengthhigh72
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 5.99 73 Debt/equitycounts in reverse: lower means more financial strength 0.04 71 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak9
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −12.81% 21 Relative strength (6 months) −36.82% 6 1-year return −37.05% 6 Distance from 200-day average −33.80% 4 Riskvery high92
How much the price swings.
Metric Value Position in group Volatility (60 days) 94.1% 97 Beta (1 year) 2.02 86 Maximum drawdown (12 months) 59.6% 94
3 dimensions without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Summit Therapeutics is pricier than similar companies
Summit Therapeutics's Price/book: 20.0, +52% against the median of a group of 10 similar companies (13.2).
Compared with 11 similar companies
| Metric | Summit Therapeutics | Position in the group | Band |
|---|---|---|---|
| Operating margin | 0.0% | Middle | |
| ROE | -220.0% | Low | |
| Debt/equity | 0.04 | Low | |
| Price/book | 20.0 | High | |
| Net margin | 0.0% | Middle |
Grey band: the middle half of the group; tick: the median; dot: Summit Therapeutics. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$0
Latest quarter · Q2 2026
Net income
-$215.7M
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $11.32B
- EPS
- -$1.06
- Volume
- 5.56M
- Daily trading
- €80.14M
- Dividend yield
- 0.00%
How Summit Therapeutics is changing
All resultsShares outstanding up 975.5% in 5 years
Profitable in 0 of 5 fiscal years
Returns
Summit Therapeutics returns
$1,000 invested in Summit Therapeutics 5 years ago, on November 17, 2021, would be worth $1,985 today: +98.52% in total, +14.70% per year. This is the price return only: dividends are excluded.
| Period | Summit Therapeutics | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −31.02% | −3.17% | $690 |
| 6 months | −36.75% | +0.11% | $632 |
| Year to date | −38.59% | +8.34% | $614 |
| 1 year | −36.64% | +11.15% | $634 |
| 3 years | +456.48% | +64.30% | $5,565 |
| 5 years | +98.52% | +58.18% | $1,985 |
| 10 years | +2.29% | +239.10% | $1,023 |
Over the last 6 months it has done better than 3% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Summit Therapeutics: technical analysis
Summit Therapeutics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 70.9% below its all-time closing high ($36.70, April 24, 2025).
- Trend
- No clear trend
- RSI (14 sessions)
- 32
- Between 30 and 70
- vs 200-session average
- −33.80%
Active signals
New 52-week low.
since November 16, 2026
Close below the low of the previous 55 sessions.
since November 16, 2026
Golden cross: the 50-session average has crossed above the 200-session average.
since November 4, 2026
Trading on November 17, 2026 was 2.3 times the 20-session average.
since November 16, 2026
Support and resistance
Price areas where Summit Therapeutics has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$15.49+45.17%10 touches, last on September 28, 2026
- Resistance$14.31+34.08%5 touches, last on November 5, 2026
- Resistance$12.29+15.18%3 touches, last on August 17, 2026
- Last price$10.67
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 2.02
- Volatility (60 sessions, annualised)
- 94.1%
- Largest fall in the last year
- −59.55%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Summit Therapeutics: seasonality
Average monthly price change over 12 years
Over the last 12 years, the strongest month for Summit Therapeutics has been December: +35.68% on average, positive in 5 years out of 11. The weakest has been June: −9.37% on average, positive in 4 years out of 12. November, the current month, has been positive in 4 years out of 11 (−1.58% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +9.33% | +15.65% | 6 of 11 |
| February | +3.56% | −2.73% | 5 of 11 |
| March | +3.93% | −2.78% | 5 of 11 |
| April | +4.26% | −1.27% | 6 of 12 |
| May | +7.59% | +0.26% | 6 of 12 |
| June | −9.37% | −8.06% | 4 of 12 |
| July | +7.22% | +2.67% | 7 of 12 |
| August | −0.26% | −1.70% | 6 of 12 |
| September | +8.92% | −0.56% | 5 of 12 |
| October | −4.82% | −6.51% | 3 of 12 |
| November | −1.58% | −1.55% | 4 of 11 |
| December | +35.68% | −2.24% | 5 of 11 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Summit Therapeutics and its competitors
Its products are marketed in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. Summit Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of medicines. Its most advanced candidate, ivonescimab, is a bispecific antibody that combines PD-1 blockade with anti-angiogenesis activity, and it is being studied for non-small cell lung cancer and colorectal cancer.
- Headquarters
- Miami, United States
- Employees
- 265
- Founded
- 2003
- Chief executive
- Robert W. Duggan
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Summit TherapeuticsSMMT | $11.32B | 0.0% | — | −36.75% |
| Bio-TechneTECH | $11.43B | 21.7% | 66.8 | +67.74% |
| BioMarin PharmaceuticalBMRN | $11.09B | 16.3% | 146.8 | +12.93% |
| Madrigal PharmaceuticalsMDGL | $9.93B | -10.7% | — | −19.42% |
| Corcept TherapeuticsCORT | $9.36B | 0.8% | 190.2 | +24.30% |
| Halozyme TherapeuticsHALO | $14.67B | 56.8% | 38.3 | +42.98% |
Same industry or related industries, similar size. Compare Summit Therapeutics with its competitors · Full profile
